Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 7

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

Authors Sinha B, Gangopadhyay KK, Ghosal S

Received 11 March 2014

Accepted for publication 19 April 2014

Published 23 June 2014 Volume 2014:7 Pages 225—228


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Video abstract presented by Binayak Sinha, Kalyan Kumar Gangopadhyay, Samit Ghosal

Views: 1898

Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal3

1Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, India

Abstract: Insulin therapy is not without side effects. In patients with complications on complex regimens, failure to attain adequate glycemic control exposes the patient to high risks and the considerable mental distress associated with failed injectable therapy. As clinicians, we felt it necessary to undertake a trial of newer therapies like insulin degludec, which according to published literature, appears to be superior to earlier basal analogs by fewer hypoglycemic episodes, better glycemic predictability, and genuine 24-hour coverage. Here we report on three cases seen in our own clinical practice where insulin degludec was used in patients experiencing inadequacies with their current basal insulin therapy (insulin glargine). Switching to insulin degludec resulted in clinically meaningful reductions in hypoglycemia, along with reduced fasting plasma glucose and glycosylated hemoglobin and improved satisfaction with treatment. We also explored the use of long-acting insulin in renal failure and the possibility of dose reduction when switching from existing basal insulin therapy.

Keywords: insulin, glargine, degludec, hypoglycaemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]